Lang Catherine E, Edwards Dorothy F, Birkenmeier Rebecca L, Dromerick Alexander W
Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO 63108, USA.
Arch Phys Med Rehabil. 2008 Sep;89(9):1693-700. doi: 10.1016/j.apmr.2008.02.022.
To estimate minimal clinically important difference (MCID) values of several upper-extremity measures early after stroke.
Data in this report were collected during the Very Early Constraint-induced Therapy for Recovery of Stroke trial, an acute, single-blind randomized controlled trial of constraint-induced movement therapy. Subjects were tested at the prerandomization baseline assessment (average days poststroke, 9.5d) and the first posttreatment assessment (average days poststroke, 25.9d). At each time point, the affected upper extremity was evaluated with a battery of 6 tests. At the second assessment, subjects were also asked to provide a global rating of perceived changes in their affected upper extremity. Anchor-based MCID values were calculated separately for the affected dominant upper extremities and the affected nondominant upper extremities for each of the 6 tests.
Inpatient rehabilitation hospital.
Fifty-two people with hemiparesis poststroke.
Not applicable.
Estimated MCID values for grip strength, composite upper-extremity strength, Action Research Arm Test (ARAT), Wolf Motor Function Test (WMFT), Motor Activity Log (MAL), and duration of upper-extremity use as measured with accelerometry.
MCID values for grip strength were 5.0 and 6.2 kg for the affected dominant and nondominant sides, respectively. MCID values for the ARAT were 12 and 17 points, for the WMFT function score were 1.0 and 1.2 points, and for the MAL quality of movement score were 1.0 and 1.1 points for the 2 sides, respectively. MCID values were indeterminate for the dominant (composite strength), the nondominant (WMFT time score), and both affected sides (duration of use) for the other measures.
Our data provide some of the first estimates of MCID values for upper-extremity standardized measures early after stroke. Future studies with larger sample sizes are needed to refine these estimates and to determine whether MCID values are modified by time poststroke.
评估卒中后早期几种上肢测量指标的最小临床重要差异(MCID)值。
本报告中的数据收集于卒中恢复超早期强制性治疗试验,这是一项关于强制性运动疗法的急性、单盲随机对照试验。受试者在随机分组前的基线评估(卒中后平均天数,9.5天)和首次治疗后评估(卒中后平均天数,25.9天)时接受测试。在每个时间点,使用一组6项测试对患侧上肢进行评估。在第二次评估时,还要求受试者对患侧上肢感知到的变化进行整体评分。基于锚定法分别计算了6项测试中患侧优势上肢和患侧非优势上肢的MCID值。
住院康复医院。
52名卒中后偏瘫患者。
不适用。
握力、上肢综合力量、动作研究臂测试(ARAT)、沃尔夫运动功能测试(WMFT)、运动活动日志(MAL)以及通过加速度计测量的上肢使用时长的估计MCID值。
患侧优势侧和非优势侧握力的MCID值分别为5.0和6.2千克。ARAT的MCID值两侧分别为12分和17分,WMFT功能评分两侧分别为1.0分和1.2分,MAL运动质量评分两侧分别为1.0分和1.1分。其他测量指标中,优势侧(综合力量)、非优势侧(WMFT时间评分)以及两侧(使用时长)的MCID值无法确定。
我们的数据提供了卒中后早期上肢标准化测量指标MCID值的一些初步估计。需要进行更大样本量的未来研究来完善这些估计,并确定MCID值是否会因卒中后时间而改变。